Connection

Perry Halushka to Cardiovascular Diseases

This is a "connection" page, showing publications Perry Halushka has written about Cardiovascular Diseases.
Connection Strength

0.748
  1. Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers. Annu Rev Pathol. 2019 01 24; 14:211-238.
    View in: PubMed
    Score: 0.367
  2. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation. 2002 Apr 09; 105(14):1620-2.
    View in: PubMed
    Score: 0.117
  3. The role of miRNAs in cardiovascular disease risk factors. Atherosclerosis. 2016 11; 254:271-281.
    View in: PubMed
    Score: 0.079
  4. The Gordon Wilson Lecture. Regulation of thromboxane A2 receptors by testosterone: implications for steroid abuse and cardiovascular disease. Trans Am Clin Climatol Assoc. 1994; 105:95-103.
    View in: PubMed
    Score: 0.066
  5. Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease. Ration Drug Ther. 1985 Jul; 19(7):1-7.
    View in: PubMed
    Score: 0.036
  6. Castration reduces platelet thromboxane A2 receptor density and aggregability. QJM. 2005 May; 98(5):349-56.
    View in: PubMed
    Score: 0.036
  7. Thromboxane A2 receptors. J Lipid Mediat Cell Signal. 1995 Oct; 12(2-3):361-78.
    View in: PubMed
    Score: 0.019
  8. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995 Jun 01; 91(11):2742-7.
    View in: PubMed
    Score: 0.018
  9. Thromboxane A2 in health and disease. Fed Proc. 1987 Jan; 46(1):131-2.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.